If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.05 (11.111%)
Market Cap: £2.15m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Options Award

23 Dec 2025 07:00

RNS Number : 5646M
Physiomics PLC
23 December 2025
 

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZZZZKGKZZ
Date   Source Headline
19th Dec 200810:46 amRNSHolding(s) in Company
12th Dec 20087:30 amRNSPlacing of Shares
27th Nov 20087:00 amRNSFinal Results
17th Nov 20087:00 amRNSPhysiomics presentation at Bio-Europe Conference
20th Aug 20087:00 amRNSPhysiomics ICSB presentation
28th Jul 20087:30 amRNSTrading Statement
14th Jul 20087:30 amRNSFurther Agreement with Eli Li
20th Jun 20083:53 pmRNSHolding(s) in Company
3rd Jun 20087:00 amRNSChronotherapy Presentation
20th May 20087:00 amRNSTempo Project Update
22nd Apr 20089:24 amRNSHolding(s) in Company
8th Apr 20087:01 amRNSAACR Presentation Update
31st Mar 20087:00 amRNSInterim Results
15th Feb 200811:33 amRNSRelated party loan
14th Feb 20087:00 amRNSManagement Appointment
13th Feb 200812:07 pmRNSPhysiomics AACR Presentation
21st Dec 200712:37 pmRNSResult of AGM
20th Dec 200711:15 amRNSBoard Changes
17th Dec 20077:00 amRNSMOU with Swansea University
12th Dec 200711:08 amRNSCollaboration Update
30th Nov 20071:54 pmRNSHolding(s) in Company
28th Nov 20077:00 amRNSFinal Results - Replacement
27th Nov 200710:33 amRNSFinal Results
24th Sep 20073:59 pmRNSHolding(s) in Company
17th Sep 20075:25 pmRNSHolding(s) in Company
17th Sep 200711:38 amRNSHolding(s) in Company
17th Sep 20079:00 amRNSCollaboration with Eli Lilly
16th Aug 20077:01 amRNSAIM rule 26 information
13th Aug 20072:35 pmRNSHolding(s) in Company
7th Aug 20074:28 pmRNSHolding(s) in Company
18th May 20074:04 pmRNSDirectorate Change
16th Mar 200711:15 amRNSInterim Results
15th Feb 20077:00 amPRNPhysiomics plc - Agreement
2nd Jan 20077:00 amRNSResult of AGM
19th Dec 20061:01 pmRNSTotal Voting Rights
7th Dec 20062:54 pmRNSNotice of AGM and prelims
7th Nov 20064:47 pmRNSHolding(s) in Company
29th Sep 20062:46 pmRNSAdditional Listing
5th Sep 20062:41 pmPRNNotice of EGM
8th Jun 200610:03 amPRNDirectorate Change
28th Apr 20067:00 amPRNHolding(s) in Company
31st Mar 20067:00 amPRNInterim Results
22nd Dec 20051:04 pmPRNAGM Statement
25th Oct 20053:02 pmPRNStatement re: Partial Investing of Share Options
18th Oct 200512:06 pmPRNDirector/PDMR Shareholding
8th Sep 20056:00 amPRNFinal Results
26th Aug 20056:00 amPRNDirectorate Change
28th Jun 200510:48 amPRNAdditional Listing
27th Jun 20056:00 amPRNStatement re share subscription and issue of options
23rd Jun 20056:00 amPRNRe Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.